# OnCo record paper-oxnard-osimertinib-resistance-mechanisms-jama-oncol-2018 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-oxnard-osimertinib-resistance-mechanisms-jama-oncol-2018/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-oxnard-osimertinib-resistance-mechanisms-jama-oncol-2018" ;
  schema:name "Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib"@en ;
  schema:description "When the newest targeted pill stops working, what happens next depends on whether the tumour kept the mutation the pill was chosen for. Two thirds lost it, and those patients relapsed much sooner and by many different routes."@en ;
  schema:url <https://onco.cc/key-papers/paper-oxnard-osimertinib-resistance-mechanisms-jama-oncol-2018/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://doi.org/10.1001/jamaoncol.2018.2969>, <https://pubmed.ncbi.nlm.nih.gov/30073261/> ;
  schema:sameAs <https://doi.org/10.1001/jamaoncol.2018.2969> ;
  schema:datePublished "2018"^^xsd:gYear ;
  schema:author "Oxnard GR, Hu Y, Mileham KF, et al." ;
  onco:related <https://onco.cc/biomarkers/egfr-t790m/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:technologies <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/continuous-ctdna-monitoring/> ;
  onco:targets <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/kras/>, <https://onco.cc/targets/met/> ;
  onco:drugs <https://onco.cc/drugs/osimertinib/>, <https://onco.cc/drugs/guardant360-cdx/> ;
  onco:institutions <https://onco.cc/institutions/dana-farber/> ;
  onco:pathways <https://onco.cc/pathways/resistance-routes-map/>, <https://onco.cc/pathways/clonal-evolution/>, <https://onco.cc/pathways/drug-tolerant-persisters/>, <https://onco.cc/pathways/rtk-activation/> ;
  onco:terms <https://onco.cc/terms/resistance/>, <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/cfdna/>, <https://onco.cc/terms/egfr-mutation-subtypes/>, <https://onco.cc/terms/biopsy/> ;
  onco:people <https://onco.cc/people/pasi-janne/> ;
  onco:journals <https://onco.cc/journals/jama-oncology/> .